Market closedNon-fractional
Cardiff Oncology/CRDF
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Cardiff Oncology
Cardiff Oncology Inc a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical program in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC").
Ticker
CRDF
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
San Diego, United States
Employees
-
Website
www.cardiffoncology.com
Cardiff Oncology Metrics
BasicAdvanced
$106M
Market cap
-
P/E ratio
-$0.90
EPS
1.88
Beta
-
Dividend rate
Price and volume
Market cap
$106M
Beta
1.88
Financial strength
Current ratio
5.91
Quick ratio
5.706
Long term debt to equity
2.136
Total debt to equity
3.279
Management effectiveness
Return on assets (TTM)
-30.66%
Return on equity (TTM)
-51.12%
Valuation
Price to revenue (TTM)
172.856
Price to book
1.73
Price to tangible book (TTM)
1.73
Price to free cash flow (TTM)
-3.443
Growth
Revenue change (TTM)
54.43%
Earnings per share change (TTM)
1.63%
3-year revenue growth (CAGR)
18.13%
3-year earnings per share growth (CAGR)
1.74%
What the Analysts think about Cardiff Oncology
Analyst Ratings
Majority rating from 4 analysts.
Cardiff Oncology Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$200K
100.00%
Net income
-$10M
7.53%
Profit margin
-5,000.00%
-46.24%
Cardiff Oncology Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.25
-$0.22
-$0.21
-$0.22
-
Expected
-$0.26
-$0.29
-$0.28
-$0.25
-$0.25
Surprise
-3.55%
-22.81%
-24.32%
-11.11%
-
Cardiff Oncology News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Cardiff Oncology stock?
Cardiff Oncology (CRDF) has a market cap of $106M as of July 27, 2024.
What is the P/E ratio for Cardiff Oncology stock?
The price to earnings (P/E) ratio for Cardiff Oncology (CRDF) stock is 0 as of July 27, 2024.
Does Cardiff Oncology stock pay dividends?
No, Cardiff Oncology (CRDF) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Cardiff Oncology dividend payment date?
Cardiff Oncology (CRDF) stock does not pay dividends to its shareholders.
What is the beta indicator for Cardiff Oncology?
Cardiff Oncology (CRDF) has a beta rating of 1.88. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Cardiff Oncology stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.